Connecting Life Sciences

page 6-7

page 8

Innovation made in Vienna:Hookipa Biotech is super-charging immunotherapies with $60 million

Life Science City Vienna:30 SMEs you must know

Celebrating Innovation in Biotech & Medtech

VIENNAHighlights Spring & Summer 2018

aws BOB - Best of Biotech is an international two-stage life science business plan competition organized by the Austria Wirtschaftsservice on behalf of the Austrian Federal Ministry for Digital and Economic Affairs. Three out of four winners chose Vienna as the city in which to set up their life sciences business. Congratulations to all the outstanding awardees!

i

© a

ws/

vogu

s

BHS Technologies (Völs), 1st prize sponsored by Shire BHS is developing a disruptive medical device that will enhance the performance of microsurgical procedures for all participants - patient, surgeon and hospital.| bhs-technologies.com

Macro Array Diagnostics (Vienna), 2nd prize sponsored by Roche Diagnostics and Roche Austria Macro Array Diagnostics is creating the first allergy test allowing a simultaneous measurement of total IgE and specific IgE covering close to 100% of globally relevant allergens.| macroarraydx.com

ImageBiopsy Lab (Vienna), 3rd prize sponsored by Boehringer Ingelheim IB Lab uses state-of-the-art computer-vision and artificial intelligence technol-ogy to change the way in which bone diseases are being assessed and diagnosed, including knee os-teoarthritis.| imagebiopsylab.com

MorphoMed (Vienna), LISAvienna Medtech Award MorphoMed focuses on tissue engineering based on its proprietary medical-silk technology. The lead product is a regenerative anterior cruciate liga-ment, which will fully restore the endogenous ligament.| morphomed.at

bestofbiotech.at

As a clear result of Austria’s current movement to promote innovation and growth, I am delighted to see a steady stream of innovative biotech and medical device start-ups opening up their doors here. Most of them have chosen Vienna as their home base.”

Why Vienna?

“

© a

ws

/ Her

iber

t Cor

n

Marlis Baurecht, Business area Entrepreneurship, Property Rights, Seedfinancing, aws

aws.at

2

Various grants, loans and guar-antees as well as free consulting

services and flexible start-up offices are available in Vienna. The increased research premium of 14% makes Austria even more attractive. We strongly recommend that you consider Vienna when planning to start up or grow your company at the heart of Europe! Our technology experts are available to talk about all the support that is available here for developing tomorrow’s prod-ucts, processes and services. Please contact us to help you find suitable lab space including the most modern start-up labs.

Did you know that all major biopharmaceutical companies ranked by sales run strategic offices in Vienna? Some even coordinate clinical trials on game-changing drugs at their premises in Austria. Other big players such as Boehringer Ingelheim, Octapharma and Ottobock make major investment decisions at their Vienna site that result in their increasing R&D and manu-facturing facilities.

Vienna is highly attractive for talent and educates the largest number of stu-dents in the German-speaking region. We are proud of hosting a vibrant international research community and a growing number of start-ups in Vien-na. On our cover, we already introduced you to some of the most promising newcomers in the city. Please see page 3 for additional start-ups and page 6-7 for more advanced companies. In addition, do not miss the opportunity to learn more about Hookipa Biotech’s recent investment deal on page 8.

We hope you enjoy reading this edition of our biannual Highlights folder. Should you wish to provide us with feedback, please contact the LISAvienna team. More up-to-date information on the life sciences sector in Austria and Vienna including new statistics and an updated directory, will be available in November.

Have a fruitful trade fair, partnering and conference season!

Peter Halwachs and Johannes SarxLISAvienna Executive Board

Contact us and benefit from our services

Newsletter & Tweets Stay updated on the hottest news from the life science city Vienna!Subscribe to our newsletter at LISAvienna.atFollow us on Twitter @lifesciencevie

in cooperation with:

Information & Consulting: Tips and contacts relating to sponsor-ship, private financing options, lab space in Vienna, development partners, lead-ing customers and internationalization

Networking & Matching: Contacts for an improved exchange of experiences and knowledge transfer as well as contact with development partners, leading cus-tomers and investors worldwide

Expertise: Analyses, background information, re-ports and studies relating to life sciences in Vienna

Marketing: Electronic and printed news items from the field of life sciences in Vienna

LISAvienna – Connecting Life SciencesWe offer core services at no chargeJoint life science platform for the advancement of life sciences in Vienna

Personalized support for innovative biotech, pharmaceutical and medical device companies- in Vienna, - that develop and market- new products, services and processes

Connecting companies with development partners and key customers.

Meet us at trade shows & exhibitions

© L

ISAv

ienna

/ Be

rane

k

Your partners at LISAvienna (ltr): Andrea Jan Coleselli (Administration, Con-trolling and Events), Johannes Sarx (Managing Director), Brigitte Tempelmaier (Project Manager Marketing & PR), Peter Halwachs (Managing Director), Martin Mayer (Technology Expert Medtech), Jürgen Fuchs (Technology Expert Biotech & Pharma)

Starting a biotech or medical device company in Vienna means benefiting from a 360° support landscape nurturing a unique life sciences ecosystem.

Dear readers!

BIO-Europe Spring 2018 Amsterdam, March 12-14, 2018

MT-Connect and MedTech Summit Nuremberg, April 11-12, 2018

BioTrinity 2018 London, April 23-25, 2018

conhIT 2018 Berlin, April 25-27

Bio€quity Europe 2018 Ghent, May 14-16, 2018

HIMSS Europe 2018 Sitges, Barcelona, May 27-29, 2018

BIO International Convention Boston, June 4-7, 2018

ACC Annual Scientific Meeting & Clinical Lab Expo Chicago, July 29 - August 2, 2018

BIO Latin America Sao Paulo, September 4-5, 2018

BIO-Europe 2018 Copenhagen, November 5-7, 2018

MEDICA & COMPAMED November 12-15, 2018

We reserve the right to make changes.

Need a lab for your start-up in Vienna?

LISAvienna has compiled a factsheet on suitable lab space. If you would like to explore options in Vienna, please contact the LISAvienna team.

Federal Ministry for Digital and Economic Affairs

3VIENNA Highlights 01/2018

STARTING UP IN VIENNA 360° Support for the Life Sciences

investinaustria.at aws.at FFG.at

We accompany you on your way to success. Enter the ecosystem now!

FWF.ac.at INiTS.at lifescienceaustria.at viennabusinessagency.at www.wko.at/wien/aw wwtf.ata

LISAvienna.at

Vienna offers an extremely tight network of funding opportunities as well as everything else needed to start up life sciences companies and en-able them to grow. Join our vibrant biotech and medical device community and become one of our skyrocketing success stories!”

Why Vienna?

“

© C

hrist

ian H

usar

NewcomersName Founded in SeedfinancingAllcyte GmbH allcyte.com 2017 xAres Genetics GmbH ares-genetics.com 2017CCORE Technology GmbH criticalcoretechnology.com 2017Contextflow GmbH contextflow.com 2016 xHeartshield heartshield.net *)IB Lab GmbH imagebiopsylab.com 2016 xMorphoMed GmbH morphomed.at 2017MVT Biotechnology GmbH mvtbio.com 2017MyeloPro Diagnostics and Research GmbH myelopro.com 2015 xNuvonis Technologies GmbH nuvonis.com 2017OVARTEC GmbH 2017PhagoMed Biopharma GmbH phagomed.com 2017Ribbon Synthetic Biolabs ribbonbiolabs.com *)

Eva Czernohorszky, Head of Technology Services, Vienna Business Agency

viennabusinessagency.at

The above list, which is not exhaustive, includes companies that opened their doors in Vienna recently as well as those that were newly added to the aws Seedfinancing portfolio in 2017. The symbol “*)” marks two start-up projects that have received significant funding via the Vienna Business Agency’s “Co-Create 2017” funding program.

Vienna has joined Start AllianceHelping ideas to spread fasterstartalliance.net

€ 800,000Seedfinancing

Access to privateequity and licensing

partners

Ideas&

Talent

Growing life science network

Shared researchinfrastructure

Experienced support

agenciesInternational

airport

Cost freecoaching

Great businessenvironment

Locatedat the heartof Europe

Flexible start-up

labs

€ 500,000for R&Dprojects

€ 200,000for Pre-

Seed

Vienna:· Highest quality of life worldwide· Largest talent pool in the German speaking region· Outstanding basic and clinical research· Prime conference destination

Austria:· Stable political and economic framework· 14% research tax credit· Maximum corporate tax rate: 25%· Tailor-made funding opportunities

Get in touch!

4

BulletinBoard

Arsanis announces closing of Initial Public OfferingArsanis, Inc. (NASDAQ:ASNS) is a clinical-stage biopharma-ceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases. The gross proceeds to Arsanis from the offering were $46.0 million, before deducting underwriting discounts and commissions and other offering expenses.arsanis.com

Boehringer Ingelheim to invest in Vienna

© Copyright Boehringer Ingelheim / Rainer Mirau

Themis raises € 10 million in series C financingThe GHIF-led investment will be used to advance

Themis’s clinical and pre-clinical vaccine development

programs, including its most advanced vaccine

against chikungunya virus, on which the company

recently reported positive Phase 2 results.

themisbio.com

APEIRON Biologics and Evotec achieve first

milestone in € 200 million immuno-oncology

alliance with Sanofi

The strategic collaboration on small molecule leads and

targets for next-generation therapies in immuno-oncology

was set up in 2015 by APEIRON Biologics, Evotec, and

Sanofi. Now, the advancement of an undisclosed, new

small molecule into late-stage pre-clinical development has

triggered a milestone payment. The € 3 million will be split

equally between the two biotech companies.

apeiron-biologics.com

SzeleSTIM to be granted H2020 phase 1 SME supportSzeleSTIM is focusing on wearable bio-electronic devices for Auricular Vagus Nerve Stimulation, allowing minimally invasive and non-pharmacological pain therapy adapted to the individual patient.szelestim.com

ENGAGE WITH THE RIGHT PARTNERS AT EUROPEʼS LARGEST SPRINGTIMEBIOTECH PARTNERING EVENT

VIENNA , AUSTRIA // MARCH 25–27, 2019

© W

ien

Tour

ismus

/ P

eter

Rig

aud

5VIENNA Highlights 01/2018

Get connected @ (@lifesciencevie)

I ViennaLexogen and IMBA:

A success story from Vienna

Lexogen, the transcriptomics and next-generation sequencing

company from Vienna, has launched the SLAMseq product

family for high throughput metabolic sequencing of RNA. Kits

are based on a new technology developed at the Austrian

Academy of Sciences’ Institute of Molecular Biotechnology

(IMBA) at the Vienna BioCenter and are already being marketed

and used around the world.

lexogen.com

Coming soon The Vienna Business Agency’s Vienna BioCenter Start-up Labsviennabusinessagency.at

Ottobock to celebrate twenty years of C-LegManufactured in Vienna only, C-Leg is the most popular computerized above-knee prosthetic leg in the world. Back in 1999, Ottobock received the Austrian Innovation Award for developing the revolutionary C-Leg.

ottobock.at

Interested in bioeconomy & biopharma?Check out technologies and ideas for joint projects available at the Austrian Centre of Industrial Biotechnology!

www.acib.at/industry

FDA grants Orphan Drug Designation to Zytoprotec’s unique dialysis fluid for the treatment of patients with end-stage renal diseaseZytoprotec is currently preparing a pivotal Phase III clinical trial with PD-protec® in 300 patients in Europe and the United States. The orphan designation will provide Zytoprotec with several development incentives including market exclusivity for up to seven years upon FDA approval.zytoprotec.com

Siemens to open Living Lab to digitalize

bioprocesses in ViennaThe lab focuses on modeling, simulating and optimizing bioprocesses.

One use case is the production of personalized drugs in small batches.

This requires manufacturing processes to become much more flexible

than today – digitalization and automation are keys to success.

siemens.com/at/de

Sempermed to introduce environmentally friendly examination glovesThe nitrile examination glove Sempercare® Green is not only green in color, this latex-free glove is produced without any rubber accelerators or chlorine and saves on gas, electricity and CO2 emissions during the production process.

reglove-yourself.com

© S

empe

rmed

ENGAGE WITH THE RIGHT PARTNERS AT EUROPEʼS LARGEST SPRINGTIMEBIOTECH PARTNERING EVENT

VIENNA , AUSTRIA // MARCH 25–27, 2019

© W

ien

Tour

ismus

/ P

eter

Rig

aud

Kick-off: Austrian BioI

maging

Industry Board (ABIB)

BioImaging Austria/CMI (Correlated Multimodal Imag-

ing Node Austria) has established an Industry Board to

connect all stakeholders interested in bioimaging and

image processing in Austria. Concerted efforts and

activities between life scientists, imaging scientists,

computer experts, and industry will foster multimodal

imaging and drive innovation.

bioimaging-austria.at

Life Sciences City Vienna: 30 SMEs you should know

DirectSens: WKW Mercur Award 2017

DirectSens develops 3rd generation biosensors, especially for carbohydrates such as lactose or glucose, that meet the needs of continuous measurements.

directsens.com

Evologic Technologies: WKW Mercur Award 2017

Evologic applies advanced technologies from red biotech to develop bioprocesses for white biotech products including mycorrhizal fungi as fertilizers for agriculture.

evologic-technologies.com

Acticell: Gewinn Award 2017

Acticell develops and sells safe and environmen-tally friendly solutions for emerging technologies in the textile industry including unusual dyeing effects or localized bleaching.

acticell.at

Vienna is proud to host award-winning enterprises!

17 companies with clinical stage pipelinesVienna’s red biotech community is particularly rich in platform technologies that are leading to promising new drug candidates and medical devices. Our unique start-up ecosystem, together with experienced entrepreneur networks and negotiation skills, have yielded spectacular equity investments and licensing deals. These are enabling product candidates to progress into clinical development stages.

Below is a list of Vienna-based companies that have succeeded in starting clinical studies. Together, these account for:

10 product candidates with ongoing phase I trials or ready for phase I

16 product candidates with ongoing phase II trials or ready for phase II

13 product candidates with ongoing phase III trials or ready for phase III

In 2017, Vienna even witnessed the European Commission’s marketing authorization for APEI-RON Biologics’ promising new antibody-based immunotherapy for a rare pediatric cancer, neuro-blastoma.

Truly overwhelming!

Name Phase I Phase II Phase III

AFFiRiS AG affiris.comActive immunization to treat or prevent chronic diseases

AOP Orphan Pharmaceuticals AG aoporphan.comInnovative solutions for rare diseases

APEIRON Biologics AG apeiron-biologics.comImmunological approaches to treat cancer

APEPTICO Forschung und Entwicklung GmbHapeptico.com Peptide-based drugs targeting life-threatening diseases

Arsanis Biosciences GmbH arsanis.comTargeted monoclonal antibodies to address infectious diseases

Biomay AG biomay.com Innovative allergy therapeutics

F4 Pharma Ges.m.b.H. i.G. f4-pharma.comDrugs targeting vascular leak syndrome and inflammation

Hookipa Biotech AG hookipabiotech.comActive immunization therapies for infectious diseases and cancer

Marinomed Biotech AG marinomed.comInnovative immunological and antiviral treatments

Nabriva Therapeutics AG nabriva.comNovel antibiotics to treat infectious diseases

Panoptes Pharma GmbH panoptes-pharma.comInnovative small molecule drugs to treat eye diseases

ProFem GmbH profem.atInnovative drugs for the treatment of gynecological diseases

Sanochemia Pharmazeutika AG sanochemia.atDiagnostics and drugs targeting neurology and oncology

Themis Bioscience GmbH themisbio.comVaccines against emerging and specialist indications

Valneva SE valneva.comInnovative life-saving vaccines against infectious diseases

Vivaldi Biosciences AG vivaldibiosciences.comDeveloping more effective flu vaccines

Zytoprotec GmbH zytoprotec.comCytoprotective therapeutics for renal replacement therapy

The above list is not exhaustive. Biologics Small Molecules

I have been living in Vienna for over 70 years, and it’s a great place. I’ve been the CEO of biotech companies in Vienna for almost 20 years, and it’s a great location for these too. We have valuable support and a positive climate (and I’m not referring to our December weather…).”

“Why Vienna?

Hans Loibner, CEO, APEIRON Biologics AG

© A

peiro

n Bi

olog

ics

Are you interested in learning more about clinical stage development projects in Vienna? LISAvienna has compiled a factsheet on 39 product candidates. Several of them are available for partnering. Please contact the LISAvienna team for further details.

7

Life Sciences City Vienna: 30 SMEs you should know

SCARLETRED: WSA Young Innovators 2017

SCARLETRED®Vision revolutionizes dermatol-ogy through standardized digital documentation and objective digital assessment of visual skin changes.

scarletredvision.com

17 companies with clinical stage pipelines 13 companies with unique eHealth expertise

Vienna is proud to be called home for a growing number of innovative eHealth companies that are suc-cessfully addressing such market niches. We have selected 13 companies that cover a plethora of topics for our brief introduction below. You are warmly invited to connect to these hot spots of eHealth expertise!

IT has revolutionized health care in recent years and there is no end in sight for this major transformation process. In actual fact, it would seem we have only just begun to understand where big data, network analysis and artificial intelligence might take us in the future. Evidently, there are many market niches for highly skilled and creative entrepreneurs.

Name Main product or service

AHIT Animal-Health-IT GmbH ahit.atInnovative applications and IT-services for agriculture, including vets and livestock owners

Animal Health Record: integrative electronic health record system for all stakeholders in animal husbandry

CogVis Software und Consulting GmbH cogvis.atSmart home products for active and assisted living

fearless life comfort system: automatic fall detection, no device needs to be worn, no camera

contextflow GmbH contextflow.comImage-based deep learning tools to improve medical decision making

contextflow search engine: a tool for radiologists to find similar reference cases and diagnoses quickly

Diagnosia Internetservices GmbH diagnosia.comTools for making evidence-based medicine simple

Diagnosia app: rapid access to information on drugs and their interplay, for medical professionals only

dwh GmbH dwh.atSystem analysis, modeling and simulation for informed decision-making

Decision support: tailor-made services for policy making, the pharmaceutical industry or health-technology assessment

ImageBiopsy Lab www.imagebiopsylab.comTools for radiologists/orthopedics to improve standardized assessment of bone diseases

Knee check-up package: a positioning device and software for tracking osteoarthritis, rheumatoid arthritis, and osteoporosis

Medexter Healthcare GmbH medexter.comImproving quality and safety in patient care by integrating intelligent clinical decision support

ArdenSuite: flexible CDS technology platform for hospitals - both patient and population specific

mySugr GmbH mysugr.comMarket leader in digital diabetes management, part of the Roche family

mySugr Bundle: unlimited test strips, an Accu-Chek® Guide meter, the mySugr app and diabetes advice wherever and whenever you want

piur imaging GmbH piurimaging.comTomographic ultrasound allowing for safe and cost-effective 3D vascular diagnostics

PIUR tUS: a tomographic function for regular ultrasound devices with a digital video output - no x-rays or contrast agent required

Platomics GmbH platomics.comDigital infrastructure for personalized medicine to support medical doctors, hospi-tals, labs and test kit providers

PlatoX™: user-friendly digitalization of workflows to analyze genes and ge-nomes - meets data security requirements

Recognosco GmbH recognosco.netProfessional speech recognition platform for efficient, high quality document crea-tion

RSDK: Software Development Kit (SDK) to speech-enable dictation and docu-ment management solutions

Scarletred Holding GmbH scarletredvision.comTools for standardized, digital skin assessment

SCARLETRED®Vision: app, patch and QR system for digital dermatology, uncoupling medical from personal data

Tiani Spirit GmbH tiani-spirit.comStandards-based interoperability in healthcare IT

Spirit Electronic Health Record: Software to standardize, connect and exchange information between healthcare systems

The above list is not exhaustive.

Austria’s healthcare and life science industry is very well known by ex-perts all over the world. We are proud to have our headquarters in Vienna and to be part of this vibrant atmosphere regarding technology, innovations and digitali-zation.”

“

Martin Tiani, CEO, Tiani Spirit GmbH

© T

iani S

pirit

LISAvienna Partnering

Tailor-made schedule to meet all the Vienna based biotech and medical device start-ups you are interested in One day in Vienna, for global players and investors only

Healthcare by Big DataAt the Complexity Science Hub Vienna, the world’s first nationwide healthcare system simulator is being developed.csh.ac.at

The proceeds of the fundraising will primarily be used to advance two proof-of-concept clinical trials of Hookipa’s lead development programs: a phase 2 study of the company’s prophylactic Cytomeg-alovirus (“CMV”) vaccine in solid organ transplant patients, and a phase 1 study of its TheraT®-based active immunization therapy in patients with head & neck squamous cell carcinoma. In addition, Hookipa plans to expand its technology platform into other areas of disease, such as prostate cancer.

Investors trust in Hookipa

The financing round was led by an undisclosed blue chip U.S. public investment fund specializ-ing in life sciences, along with other new investors: HBM Partners, Hillhouse Capital, Sirona Capital and strategic investor Gilead. All current Hookipa investors - Sofinnova Partners, Forbion Capital Part-ners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners - participated in the round.

LISAvienna Life Science Austria Vienna Walcherstrasse 11A1020 Vienna, Austria

PHONE + 43 (0) 1 50175 358FAX + 43 (0) 1 50175 900E-MAIL office@LISAvienna.atWEB www.LISAvienna.at

Layo

ut:

Eva

Aic

hin

ge

r

Innovation made in Vienna: Hookipa Biotech is supercharging immunotherapies with $60 million

Hookipa Biotech AG, a clinical stage biotech company pioneering an innovative class of immune activation therapies for oncology and infectious diseases in Vienna, recently announced that it has raised $59.6 million (€50.0 million) in an oversubscribed Series C financing.

Smart facilities in smart cities

Founded in Vienna back in 2011, Hookipa today operates facilities at the Vienna BioCenter, which is one of Austria’s most well-known biotech hot spots, In 2017 Hookipa decided to open a US site at the Alexandria Bio Incubator in New York where Chief Medical Officer Igor Matushansky and Head of Clini-cal Programs Andy Hwang are based.

The Austrian capital is an important and competitive hub at the center of Europe’s biotech and life sciences sector. It provides an environment that is forward-looking, dynamic, and challenging, which in turn increases the industry´s capacity to innovate.”

Why Vienna?

“

Experienced team promoting a great pipeline

Hookipa Biotech stands out from the European biotech community thanks to its highly innovative platform technologies and its ability to raise sig-nificant amounts of capital to move its promising clinical-stage drug candidates forward. Hookipa’s team, which represents a melting pot of exper-tise and heterogeneous networks, is the secret of its success: The company benefits from many years of experience in collaborating with the pri-vate equity sector, from partnering with research communities worldwide and from gaining essen-tial industry know-how from distinguished players such as Bayer, Baxter, Evotec, Daiichi Sankyo, GlaxoSmithKline, MorphoSys, Novartis, uniQure and Valneva.

hookipabiotech.com

LISAvienna is a joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry for Digital and Economic Affairs and the City of Vienna, LISAvienna contributes to the advance-ment of life sciences in Vienna.

Joern Aldag CEO Hookipa Biotech AG

JAldag@hookipabiotech.com

© H

ookip

a Bi

otec

h

© Hookipa Biotech © Hookipa Biotech

Hookipa Biotech at a glance

• Founded in 2011

• 51 employees

• Arenavirus-based vector technologies TheraT® and Vaxwave® available for strategic partnerships to develop next generation immunotherapies

• Headquarters located at the Vienna BioCenter